Characterization of a novel human immunodeficiency virus type 1 protease inhibitor, A-790742

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1337-1344

  Dekhtyar, Tatyana ^a,b   Ng, Teresa I ^a   Lu, Liangjun ^a   Masse, Sherie ^a   DeGoey, David A ^a   Flosi, William J ^a   Grampovnik, David J ^a   Klein, Larry L ^a   Kempf, Dale J ^a   Molla, Akhteruzzaman ^a  

^a ABBOTT LABORATORIES   (United States)

^b AP52 N ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 790742; ATAZANAVIR; DARUNAVIR; LOPINAVIR; PROTEINASE INHIBITOR; TIPRANAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR CLONING; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION;

DRUG RESISTANCE, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PHENOTYPE; PYRIMIDINONES; SELECTION (GENETICS); SERIAL PASSAGE;

EID: 42049100105     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01132-07     Document Type: Article

References (44)

1. Boden, D., A. Hurley, L. Zhang, Y. Cao, Y. Guo, E. Jones, J. Tsay, J. Ip, C. Farthing, K. Limoli, N. Parkin, and M. Markowitz. 1999. HIV-1 drug resistance in newly infected individuals. JAMA 282:1135-1141.
2. Carrillo, A., K. D. Stewart, H. L. Sham, D. W. Norbeck, W. E. Kohlbrenner, J. M. Leonard, D. J. Kempf, and A. Molla. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:7532-7541.
3. Cingolani, A., A. Antinori, M. G. Rizzo, R. Murri, A. Ammassari, F. Baldini, S. Di Giambenedetto, R. Cauda, and A. De Luca. 2002. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study. AIDS 16:369-379.
4. Colonno, R., R. Rose, C. McLaren, A. Thiry, N. Parkin, and J. Friborg. 2004. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J. Infect. Dis. 189:1802-1810.
5. Cvetkovic, R. S., and K. L. Goa. 2003. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63:769-802.
6. Reference deleted.
7. de Mendoza, C., L. Martin-Carbonero, P. Barreiro, B. Diaz, E. Valencia, I. Jimenez-Nacher, O. Gallego, M. Nunez, J. Gonzalez-Lahoz, and V. Soriano. 2002. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin. Trials 3:304-309.
8. Demeter, L. M., M. D. Hughes, R. W. Coombs, J. B. Jackson, J. M. Grimes, R. J. Bosch, S. A. Fiscus, S. A. Spector, K. E. Squires, M. A. Fischl, S. M. Hammer, et al. 2001. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. Ann. Intern. Med. 135:954-964.
9. Gong, Y. F., B. S. Robinson, R. E. Rose, C. Deminie, T. P. Spicer, D. Stock, R. J. Colonno, and P. F. Lin. 2000. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob. Agents Chemother. 44:2319-2326.
10. Grabar, S., C. Pradier, E. Le Corfec, R. Lancar, C. Allavena, M. Bentata, P. Berlureau, C. Dupont, P. Fabbro-Peray, I. Poizot-Martin, and D. Costagliola. 2000. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 14:141-149.
11. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 283:2417-2426.
12. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempf, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68:2016-2020.
13. Kantor, R., W. J. Fessel, A. R. Zolopa, D. Israelski, N. Shulman, J. G. Montoya, M. Harbour, J. M. Schapiro, and R. W. Shafer. 2002. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob. Agents Chemother. 46:1086-1092.
14. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
15. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
16. Kempf, D. J., K. C. Marsh, J. F. Denissen, E. McDonald, S. Vasavanonda, C. A. Flentge, B. E. Green, L. Fino, C. H. Park, X. P. Kong, et al. 1995. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA 92:2484-2488.
17. Kempf, D. J., J. F. Waring, D. C. Morfitt, P. Werner, B. Ebert, M. Mitten, B. Nguyen, J. T. Randolph, D. A. DeGoey, L. L. Klein, and K. Marsh. 2006. Practical preclinical model for assessing the potential for unconjugated hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors. Antimicrob. Agents Chemother. 50:762-764.
18. Ledergerber, B., M. Egger, M. Opravil, A. Telenti, B. Hirschel, M. Battegay, P. Vernazza, P. Sudre, M. Flepp, H. Furrer, P. Francioli, R. Weber, et al. 1999. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 353:863-868.
19. Little, S. J. 2000. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antivir. Ther. 5:33-40.
20. Little, S. J., E. S. Daar, R. T. D'Aquila, P. H. Keiser, E. Connick, J. M. Whitcomb, N. S. Heilmann, C. J. Petropoulos, L. Sutton, J. A. Pitt, E. S. Rosenberg, R. A. Koup, B. D. Walker, and D. D. Richman. 1999. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 282:1142-1149.
21. Lum, P. Y., Y. D. He, J. G. Slatter, J. F. Waring, N. Zelinsky, G. Cavet, X. Dai, O. Fong, R. Gum, L. Jin, G. E. Adamson, C. J. Roberts, D. B. Olsen, D. J. Hazuda, and R. G. Ulrich. 2007. Gene expression profiling of rat liver reveals a mechanistic basis for ritonavir-induced hyperlipidemia. Genomics 90:464-473.
22. MacArthur, R. D., R. M. Novak, G. Peng, L. Chen, Y. Xiang, K. H. Hullsiek, M. J. Kozal, M. van den Berg-Wolf, C. Henely, B. Schmetter, and M. Dehlinger. 2006. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST study): a long-term randomised trial. Lancet 368:2125-2135.
23. Manfredi, R., and F. Chiodo. 2001. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. 42:181-188.
24. Marcelin, A. G., I. Cohen-Codar, M. S. King, P. Colson, E. Guillevic, D. Descamps, C. Lamotte, V. Schneider, J. Ritter, M. Segondy, H. Peigue-Lafeuille, L. Morand-Joubert, A. Schmuck, A. Ruffault, P. Palmer, M. L. Chaix, V. Mackiewicz, V. Brodard, J. Izopet, J. Cottalorda, E. Kohli, J. P. Chauvin, D. J. Kempf, G. Peytavin, and V. Calvez. 2005. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 49:1720-1726.
25. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
26. Masquelier, B., D. Breilh, D. Neau, S. Lawson-Ayayi, V. Lavignolle, J. M. Ragnaud, M. Dupon, P. Morlat, F. Dabis, and H. Fleury. 2002. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 46:2926-2932.
27. Mo, H., L. Lu, T. Dekhtyar, K. D. Stewart, E. Sun, D. J. Kempf, and A. Molla. 2003. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antivir. Res. 59:173-180.
28. Mo, H., L. Lu, R. Pithawalla, D. J. Kempf, and A. Molla. 2004. Complementation in cells cotransfected with a mixture of wild-type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes of mutant variants in a single-cycle HIV resistance assay. J. Clin. Microbiol. 42:4169-4174.
29. Mo, H., T. Dekhtyar, L. Lu, S. Masse, T. I. Ng, D. A. DeGoey, L. L. Klein, D. J. Kempf, and A. Molla. 2005. In vitro selection and characterization of HIV-1 with reduced susceptibility to A-790742, a novel HIV-1 protease inhibitor potent against multi-PI resistant mutants, abstr. H-1092. Abstr. 45th Int. Conf. Antimicrob. Agents. Chemother. American Society for Microbiology, Washington, DC.
30. Molla, A., S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1998. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262.
31. Parkin, N., C. Chappey, L. Maroldo, M. Bates, N. S. Hellmann, and C. J. Petropoulos. 2002. Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J. Acquir. Immun. Defic. Syndr. 31:128-136.
32. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
33. Périard, D., A. Telenti, P. Sudre, J. J. Cheseaux, P. Halfon, M. J. Reymond, S. M. Marcovina, M. P. Glauser, P. Nicod, R. Darioli, V. Mooser, et al. 1999. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100:700-705.
34. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
35. Sham, H. L., D. J. Kempf, A. Molla, K. C. Marsh, G. N. Kumar, C. M. Chen, W. Kati, K. Stewart, R. Lal, A. Hsu, D. Betebenner, M. Korneyeva, S. Vasavanonda, E. McDonald, A. Saldivar, N. Wideburg, X. Chen, P. Niu, C. Park, V. Jayanti, B. Grabowski, G. R. Granneman, E. Sun, A. J. Japour, J. M. Leonard, J. J. Plattner, and D. W. Norbeck. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:3218-3224.
36. Tisdale, M., R. E. Myers, B. Maschera, N. R. Parry, N. M. Oliver, and E. D. Blair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710.
37. van Leeuwen, R., C. Katlama, R. L. Murphy, K. Squires, J. Gatell, A. Horban, B. Clotet, S. Staszewski, A. van Eeden, N. Clumeck, M. Moroni, A. T. Pavia, R. E. Schmidt, J. Gonzalez-Lahoz, J. Montaner, F. Antunes, R. Gulick, D. Banhegyi, M. van der Valk, P. Reiss, L. van Weert, F. van Leth, V. A. Johnson, J. P. Sommadossi, and J. M. Lange. 2003. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17:987-999.
38. Van Vaerenbergh, K. 2001. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Verh. K. Acad. Geneeskd. Belg. 63:447-473.
39. Volberding, P. A. 1999. Advances in the medical management of patients with HIV-1 infection: an overview. AIDS 13(Suppl. 1):S1-S9.
40. Walmsley, S., B. Bernstein, M. King, J. Arribas, G. Beall, P. Ruane, M. Johnson, D. Johnson, R. Lalonde, A. Japour, S. Brun, and E. Sun. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. 346:2039-2046.
41. Waring, J., R. Ciurlionis, K. Marsh, L. L. Klein, D. A. DeGoey, J. T. Randolph, B. Spear, and D. J. Kempf. 2005. Identification of proteasome gene regulation in a rat model for HIV-induced hyperlipidemia using microarray analysis, abstr. 839. 12th Conf. Retrovir. Opportun. Infect., Boston, MA.
42. Yeni, P., D. A. Cooper, J. P. Aboulker, A. G. Babiker, D. Carey, J. H. Derbyshire, M. Floridia, P. M. Girard, R. L. Goodall, M. H. Hooker, A. Mijch, V. Meiffredy, and B. Salzberger. 2006. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 368:287-298.
43. Yeni, P. G., S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2004. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA 292:251-265.
44. Zell, S. C. 2003. Clinical vignette in antiretroviral therapy: jaundice. J. Int. Assoc. Physicians AIDS Care 2:133-139.